AC
MRNA icon

Avestar Capital’s Moderna MRNA Stock Holding History

Avestar Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,495
Closed -$296K – 491
2024
Q2 		$296K Buy
2,495
+608
+32% +$76.9K 0.03% 334
2024
Q1 		$201K Buy
+1,887
New +$190K 0.02% 428
2022
Q3 		– Sell
-307
Closed -$44K – 305
2022
Q2 		$44K Buy
+307
New +$43.9K 0.01% 280
2022
Q1 		– Sell
-5,438
Closed -$916K – 440
2021
Q4 		$1.38M Sell
5,438
-844
-13% -$247K 0.17% 129
2021
Q3 		$2.42M Sell
6,282
-3,421
-35% -$1.26M 0.31% 70
2021
Q2 		$2.28M Buy
9,703
+184
+2% +$32.9K 0.31% 85
2021
Q1 		$1.7M Buy
9,519
+1,238
+15% +$179K 0.38% 47
2020
Q4 		$865K Buy
8,281
+3,340
+68% +$338K 0.24% 79
2020
Q3 		$347K Buy
+4,941
New +$345K 0.11% 146

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Avestar Capital's MRNA Position: Q3 2024 in Review

Avestar Capital sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,495 shares — an estimated $296K sold.

Avestar Capital first reported a position in MRNA in Q3 2020 and held it in 9 quarters. The position peaked at $2.42M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Avestar Capital reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Avestar Capital sold 2,495 Moderna shares in Q3 2024, an estimated $296K.
  • Avestar Capital first reported a position in Moderna in Q3 2020 and held it in 9 quarters.
  • Avestar Capital's Moderna position peaked at $2.42M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Avestar Capital's 13F filing for Q3 2024, filed 13 Nov 2024.